Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Genomics and personalized medicine: Is it really different this time?

J. Leonard Lichtenfeld, MD
Meds
June 24, 2013
624 Shares
Share
Tweet
Share

american cancer societyAnother year and another annual meeting for the American Society of Clinical Oncology in Chicago. This is a meeting that regularly attracts many thousands of doctors, researchers, pharmaceutical folks and others interested in the science and business of cancer from around the globe to learn, to discuss, to persuade, to educate on the progress being made in clinical cancer research and treatment.

And like every year, there are themes that emerge, that tend to dominate the discussions. And there are other themes that aren’t so visible, that don’t get as much attention yet in my mind are equally important as they reflect not only on the item of the moment but on how we deliver on the promises we have made in the past and the hopes we all have for the future.

Clearly, the dominant and visible theme at this year’s gathering is personalized medicine.

What strikes me about this topic is that over the past year it has gone from a “niche” discussion to a dominant theme not only here at ASCO but everywhere I turn. I am even seeing routine television news shows and commentators talking about the promise of personalized medicine. A talk that I planned six months ago to deliver in a couple of weeks from now in Boston where I was going to discuss (once again) the promise of personalized medicine in cancer care is now passé. Everyone knows about it, thanks to the incredible coverage it has been receiving literally everywhere. Now anyone who has been paying attention to the evening news could give that talk. The topic is ubiquitous.

So what is personalized medicine? At heart, what this is all about is harnessing our exploding knowledge of the human genome and applying it to the treatment of severe disease for individuals based on genetic analysis. Our focus today is on cancer, but other diseases such as degenerative brain diseases also will be impacted by our knowledge of the human genome.

As I sat in a lecture yesterday afternoon on the topics of genomics and personalized medicine, I was amazed about how much knowledge we have garnered in what appears to be such a short period of time. We now are hearing about new approaches to analyze how cancer cells work to discover master regulatory cells. The promise, of course, now that we have insight into the pathways of how cancer cells work internally is that we can target our efforts to those master regulators and conquer them, thus converting the cancer cell back to normality. Sounds simple, but it’s not. And it has taken a lot of research to get us to that point.

So one comes away from those discussions imbued with a new enthusiasm that the cure is around the corner. We are almost there. We will succeed–hopefully in the very near term.

But then I pinch myself and say, “Really?”

I do not want to be misunderstood about what I am going to write next. I am very enthusiastic about the progress we are making, perhaps more so than any time in my career. This time may be different. At least a lot of people–including me–think so. But I have been here before, and I am seeing signs that give me a moment’s pause to reflect whether everyone could be so right.

I had a chance to see one of my colleagues from my early training days while walking in the hall yesterday. I took the opportunity to reminisce about some of our experiences back then. When we started our training we had the opportunity to work with a new drug for small cell lung cancer. We treated a patient with that drug–one of the first to receive it–and he had a miraculous response. Imagine how we all felt at that moment: we had witnessed a major advance in cancer treatment for a disease that was uniformly fatal in short order. We had a “win.” But it wasn’t the win we thought it was. As we gained experience and reality over the next many years, it became clear it was in fact a small step in a disease that has proven refractory to further advances decades later.

Why do I bring this up? Because as I recounted the memory with my friend I shared my concern that we may be seeing some of the same history repeat itself: drugs that work miraculously for diseases that are difficult to treat, generating huge enthusiasm, but as we get more experience we find that our successes don’t last a long time except for a small number of patients.

And my colleague said, “This time is different.” Everyone is saying this time is different. I certainly hope so. But maybe I am not completely convinced.

There is something in investing called a contrarian indicator: when the cab driver tells you his latest stock tip or a major national newspaper has a front page headline extolling the success of the stock market, it’s time to get out. Now that personalized medicine is hot on everyone’s lips, does that mean the same for its promise?

What we tend to forget are the lectures that others have given here at ASCO meetings in the recent past talking about the frustrations of their careers working with a single mutation, such as KRAS. We forget the promises of other targeted therapies that haven’t held up as expected. We forget the enthusiasm we had when Gleevec® put chronic leukemia under control (a truly remarkable event) and the disappointment when other targeted therapies came along and didn’t have the same degree of benefit for other cancers.

Last evening I attended a lecture about the promise of immunotherapy in cancer treatment. Truly amazing advances in harnessing the immune system are now resulting in treatments that finally have given some hope to patients with previously refractory cancers. This is meaningful progress.

But during that lecture, the speaker flashed a picture of a legendary scientist/clinician who was one of the major leaders in immunotherapy research. The picture was from the cover of Time–in the mid 1970’s. I remember that cover and I remember the story that appeared in the magazine. It was the incredible story of how we were going to harness the immune system to help our bodies recognize the cancer “invaders” and get rid of those cells the same we got rid of viruses.

The speaker last night went on to extol the promise of immunotherapy. What he did not dwell on was the fact that the same promises were made 40 years ago. Along the way, the failures have been legendary. Things didn’t exactly turn out the way we expected when that article was written a long, long time ago. Yes, we now have some successes but we have no cures. We still have a way to go. It has taken a long time for immunology research to deliver the goods. No one back in 1970 thought it would take that long. This was exciting research back then. They said, “This time it’s different.” Promise you: I was there, and I do remember. And it wasn’t different–perhaps until now, 4 decades later.

I hope this time is different. I hope my caution is misplaced. I hope the suggestion that this is going to be more complicated than it appears at this moment is flat out wrong. And nothing I write here today should suggest that do not stand in awe of the incredible researchers–both those who work in the laboratories and those at the bedside–who are among the most dedicated and brilliant people that I know.

We have been witness to irrational exuberance in the past. And I hope we can deliver on great promises, and will deliver on those promises. It just may not be as easy or convenient as some would like to have us believe. We still have a long way to go.

J. Leonard Lichtenfeld is deputy chief medical officer, American Cancer Society. He blogs at Dr. Len’s Cancer Blog.

Prev

A pediatrician's approach to dehydration in children

June 24, 2013 Kevin 1
…
Next

Medical students: Embrace the joy now before it's too late

June 25, 2013 Kevin 11
…

Tagged as: Genetics, Oncology/Hematology

Post navigation

< Previous Post
A pediatrician's approach to dehydration in children
Next Post >
Medical students: Embrace the joy now before it's too late

More by J. Leonard Lichtenfeld, MD

  • Why won’t unproven COVID treatments go away?

    J. Leonard Lichtenfeld, MD
  • How can we improve the quality of medications?

    J. Leonard Lichtenfeld, MD
  • Sunscreens: The balancing act between safety and cancer prevention

    J. Leonard Lichtenfeld, MD

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
  • Recent Posts

    • Overcoming the lies of depression: Senator John Fetterman’s struggle with mental health

      Harvey Max Chochinov, MD, PhD | Conditions
    • Master the ABIM Certification exam with effective strategies: insider tips for success

      Farzana Hoque, MD | Education
    • A mentor’s legacy in medicine, leadership, and embracing evidence-based care

      Arthur Lazarus, MD, MBA | Physician
    • Breaking free from restrictive covenants to combat burnout

      Raya E. Kheirbek, MD | Physician
    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • From medical student to intern: Discovering a deeper connection with patients

      Johnathan Yao, MD, MPH | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma
  • Artificial Intelligence Could Improve Medical Practice -- But Only if Done Right
  • Huntington's Disease Chorea Improved With Valbenazine
  • T-DXd Proves Mettle in Multiple Solid Tumors
  • Preoperative Ocular Surface Disease Algorithm Re-Introduced

Meeting Coverage

  • CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma
  • T-DXd Proves Mettle in Multiple Solid Tumors
  • Preoperative Ocular Surface Disease Algorithm Re-Introduced
  • Omitting RT Safe in Many Locally Advanced Rectal Cancers
  • Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma
  • Most Popular

  • Past Week

    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • A physician’s typical day, as envisioned by a non-clinician health care MBA: a satire

      Jennifer Lycette, MD | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
  • Past 6 Months

    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • An inspiring tribute to an exceptional radiologist who made a lasting impact

      Kim Downey, PT | Conditions
  • Recent Posts

    • Overcoming the lies of depression: Senator John Fetterman’s struggle with mental health

      Harvey Max Chochinov, MD, PhD | Conditions
    • Master the ABIM Certification exam with effective strategies: insider tips for success

      Farzana Hoque, MD | Education
    • A mentor’s legacy in medicine, leadership, and embracing evidence-based care

      Arthur Lazarus, MD, MBA | Physician
    • Breaking free from restrictive covenants to combat burnout

      Raya E. Kheirbek, MD | Physician
    • Fixing the system and prioritizing patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • From medical student to intern: Discovering a deeper connection with patients

      Johnathan Yao, MD, MPH | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Genomics and personalized medicine: Is it really different this time?
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...